Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Purchased by Woodline Partners LP

Woodline Partners LP raised its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 20.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 300,504 shares of the company's stock after purchasing an additional 50,000 shares during the period. Woodline Partners LP owned about 1.02% of Dianthus Therapeutics worth $6,551,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in DNTH. TCG Crossover Management LLC bought a new stake in shares of Dianthus Therapeutics in the fourth quarter valued at about $32,735,000. Braidwell LP increased its position in Dianthus Therapeutics by 144.4% during the 4th quarter. Braidwell LP now owns 1,206,589 shares of the company's stock valued at $26,304,000 after purchasing an additional 712,902 shares during the period. Vestal Point Capital LP increased its position in Dianthus Therapeutics by 172.2% during the 4th quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company's stock valued at $23,435,000 after purchasing an additional 680,000 shares during the period. Octagon Capital Advisors LP raised its holdings in shares of Dianthus Therapeutics by 20.8% in the 4th quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company's stock valued at $46,002,000 after purchasing an additional 363,500 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. purchased a new stake in shares of Dianthus Therapeutics in the 4th quarter worth approximately $3,924,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Trading Down 2.7%

Shares of DNTH stock traded down $0.49 during trading hours on Tuesday, reaching $17.93. 296,301 shares of the company's stock were exchanged, compared to its average volume of 273,818. Dianthus Therapeutics, Inc. has a fifty-two week low of $13.37 and a fifty-two week high of $32.27. The stock's 50 day moving average is $19.09 and its 200-day moving average is $21.65. The company has a market cap of $576.63 million, a price-to-earnings ratio of -7.17 and a beta of 1.48.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.86) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The firm had revenue of $1.16 million for the quarter, compared to the consensus estimate of $0.81 million. Equities analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Guggenheim reissued a "buy" rating and set a $84.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Wedbush reaffirmed an "outperform" rating and set a $36.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Robert W. Baird reduced their price target on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a research report on Tuesday, May 13th. Finally, HC Wainwright restated a "buy" rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Tuesday, May 13th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $53.00.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.